mike.smith@pharmaphorum.com, Author at - Page 2 of 2

Trending

About Mike Smith

Posts by Mike Smith:

Pharma’s reputation problem goes beyond pricing – people don’t know what it stands for

Pharma’s reputation problem goes beyond pricing – people don’t know what it stands for

Matthew Hare-Scott argues that renewed attacks on the industry from politicians have much to do with pharma losing

X

Pharma’s reputation problem goes beyond pricing – people don’t know what it stands for

https://pharmaphorum.com/views-and-analysis/pharmas-reputation-problem-goes-beyond-pricing-people-dont-know-what-it-stands-for/

AstraZeneca and lung cancer: the pharmaphorum podcast

AstraZeneca and lung cancer: the pharmaphorum podcast

This episode of the pharmaphorum podcast focuses on lung cancer, with AstraZeneca’s VP, global franchise head, Tagrisso TDR

X

AstraZeneca and lung cancer: the pharmaphorum podcast

https://pharmaphorum.com/podcast/astrazeneca-and-lung-cancer

Lung cancer’s patient information gap: the pharmaphorum podcast

Lung cancer’s patient information gap: the pharmaphorum podcast

For episode 13 of the pharmaphorum podcast podcast I went to AstraZeneca’s London base to meet Paul Naish,

X

Lung cancer’s patient information gap: the pharmaphorum podcast

https://pharmaphorum.com/podcast/lung-cancers-patient-information-gap

ASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trial

ASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trial

Kantar analyst Katie Stockstill discusses the results of phase 3 SOPHIA trial that were presented on the last

X

ASCO 2019 – Kantar considers MacroGenics’ phase 3 SOPHIA trial

https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/kantar-macrogenics-phase-3-sophia-trial/

ASCO 2019 – Kantar debates results from the KEYNOTE-062 trial

ASCO 2019 – Kantar debates results from the KEYNOTE-062 trial

There were a number of debate-worthy outcomes from the KEYNOTE-062 trial that was presented at ASCO 2019 in

X

ASCO 2019 – Kantar debates results from the KEYNOTE-062 trial

https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-kantar-debate-results-from-keynote-062-trial/

ASCO 2019 – Kantar reviews results from phase 3 POLO trial

ASCO 2019 – Kantar reviews results from phase 3 POLO trial

Lynparza is paving new ground in pancreatic cancer, aiming to establish a maintenance setting and patient segmentation based

X

ASCO 2019 – Kantar reviews results from phase 3 POLO trial

https://pharmaphorum.com/spotlight/asco-2019-and-the-future-of-oncology/asco-2019-kantar-phase-3-polo-trial/

Biotech strategy and nanomedicine: the pharmaphorum podcast

Biotech strategy and nanomedicine: the pharmaphorum podcast

For episode 5 of the pharmaphorum podcast Dominic Tyer met Blueberry Therapeutics’ CEO Dr John Ridden at The

X

Biotech strategy and nanomedicine: the pharmaphorum podcast

https://pharmaphorum.com/r-d/biotech-strategy-and-nanomedicine/

1 2

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com